« Glucagon-Like Peptide Receptor Agonists (GLP-1 Receptor agonists): A Powerful Addition to Foundational Therapy Kidney Care in Patients With Type 2 Diabetes Mellitus ». Canadian Diabetes & Endocrinology Today, vol. 2, nᵒ 3, novembre 2024, p. 33–37, https://doi.org/10.58931/cdet.2024.2333.